EGFR and head and neck squamous cell carcinoma: Therefore, HNSCC cell lines can be divided into subsets defined by sensitivity to EGFR and FGFR-specific inhibitors, which suggest FGFR inhibitors may represent novel therapeutics alone or in combination with EGFR inhibitors.